TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05280041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOLENA - Online self-help program for older adults who lost the partner
Description: SOLENA follows the most relevant CBT elements of interventions for prolonged grief: 1) Exposure, e.g., telling the story of the loss; 2) cognitive reappraisal or restructuring of individual dysfunctional thoughts associated with the loss; 3) integration and restoration including self-care and social reengagement; and 4) behavioural activation. SOLENA's content is provided through a conversational virtual agent, Sol, who guides the user through the Study section the CBT intervention itself. In 10 study modules that address either the acceptance of the loss or the restoration and adaptation to a new life, SOLENA includes 1) readings, i.e., texts based about grief related topics that provide the background and rational for the module; and 2) exercises to encourage mourners to actively reflect on their grief and apply their new knowledge to their daily life and to practise the new routines regularly. SOLENA also provides users with the Notebook, Activities, and My Support sections.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOLENA - Online self-help program for older adults who lost the partner
Description: SOLENA follows the most relevant CBT elements of interventions for prolonged grief: 1) Exposure, e.g., telling the story of the loss; 2) cognitive reappraisal or restructuring of individual dysfunctional thoughts associated with the loss; 3) integration and restoration including self-care and social reengagement; and 4) behavioural activation. SOLENA's content is provided through a conversational virtual agent, Sol, who guides the user through the Study section the CBT intervention itself. In 10 study modules that address either the acceptance of the loss or the restoration and adaptation to a new life, SOLENA includes 1) readings, i.e., texts based about grief related topics that provide the background and rational for the module; and 2) exercises to encourage mourners to actively reflect on their grief and apply their new knowledge to their daily life and to practise the new routines regularly. SOLENA also provides users with the Notebook, Activities, and My Support sections.
Study: NCT04321317

Intervention type: OTHER
Group type: OTHER
Intervention: Measure of body composition by Air Displacement Plethysmography (ADP)
Description: Each patient included will have one measure of body composition by Air Displacement Plethysmography (ADP) during the initial consultation in the referent center for food disorders of Lyon and one year later.
Study: NCT06553911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence-based medical imaging interpretation
Description: In the AI interpretation group, using clinical information, imaging data, and corresponding etiological results of the study participants, an AI diagnostic tool is established to specifically recognize patients' chest medical imaging and construct corresponding diagnostic conclusions.
Study: NCT05270993

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-CREST group
Description: A 6-week home-based cardiac rehabilitation programme where participants will receive an I-CREST app (to deliver education, medication reminders, exercise and vital monitoring) and a wearable smartwatch device (to track physical activity). Participants will be remotely supervised by the cardiac rehabilitation team via an I-CREST web-portal. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
Study: NCT05296161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Personalized B cell tailored ocrelizumab treatment
Study: NCT05475808

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Static wrist splint treatment
Description: Static wrist splint (volar wrist cock-up orthosis): It extends from the proximal of the metacarpophalangeal (MCP) joint to the distal 2/3 of the forearm, supports the wrist from the volar face. It stabilizes the wrist in 20-30 degrees of dorsiflexion and restricts wrist movements. It allows movement of the MCP joints. Patients will be asked to wear this splint continuously at night and for at least 4 hours during the day for 8 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Static wrist splint treatment
Description: Static wrist splint (volar wrist cock-up orthosis): It extends from the proximal of the metacarpophalangeal (MCP) joint to the distal 2/3 of the forearm, supports the wrist from the volar face. It stabilizes the wrist in 20-30 degrees of dorsiflexion and restricts wrist movements. It allows movement of the MCP joints. Patients will be asked to wear this splint continuously at night and for at least 4 hours during the day for 8 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Static wrist splint treatment
Description: Static wrist splint (volar wrist cock-up orthosis): It extends from the proximal of the metacarpophalangeal (MCP) joint to the distal 2/3 of the forearm, supports the wrist from the volar face. It stabilizes the wrist in 20-30 degrees of dorsiflexion and restricts wrist movements. It allows movement of the MCP joints. Patients will be asked to wear this splint continuously at night and for at least 4 hours during the day for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tendon and nerve gliding exercises
Description: Tendon and nerve gliding exercises will be applied 5 sessions a day for 8 weeks. Each session will hold 10 repetitions and approximately 7 seconds in each exercise position.~These exercises involve a sequence of finger movements (for tendon gliding) and wrist and fingers movements (for median nerve gliding).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wrist local steroid injection
Description: Wrist local steroid injection:~After proper area cleaning with povidone solution, 1ml Betamethasone dipropionate + Betamethasone sodium phosphate (6.43 mg/ml + 2.63 mg/ml) steroid injection will be applied around the median nerve with a 22 G injector from ulnar side of the wrist proximal crease under ultrasound guidance.
Study: NCT04603183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Patients will receive abemaciclib 150 mg orally twice daily (BID) (300 mg daily, administered as six 50 mg tablets) during each 28 day cycle combined with either letrozole or fulvestrant.
Study: NCT06385951

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Procedure for patients
Description: We will screen patients who undergo an MRI and neuropsychological examination as part of their diagnostic workup. If inclusion and exclusion criteria are met, patients will be asked to undergo additional investigations (FDG-PET, lumbar puncture, tau and amyloid PET and the ALLO iVR task).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Procedure for healthy controls
Description: Healthy controls will be asked to undergo a neuropsychological examination, the ALLO iVR task, an MRI, FDG-PET and tau-PET.
Study: NCT05803850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HNC1058 Capsules
Description: HNC1058 Capsules/Placebos, single dose, PO, starting dose of 10 mg escalating up to 80 mg；HNC1058 Capsules/Placebos, 50 mg, single dose, FED.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HNC1058 Capsules
Description: HNC1058 Capsules/Placebos, single dose, PO, starting dose of 10 mg escalating up to 80 mg；HNC1058 Capsules/Placebos, 50 mg, single dose, FED.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HNC1058 Capsules
Description: HNC1058 Capsules/Placebos, single dose, PO, starting dose of 10 mg escalating up to 80 mg；HNC1058 Capsules/Placebos, 50 mg, single dose, FED.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HNC1058 Capsules
Description: HNC1058 Capsules/Placebos, single dose, PO, starting dose of 10 mg escalating up to 80 mg；HNC1058 Capsules/Placebos, 50 mg, single dose, FED.
Study: NCT05552508

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Participants will receive benralizumab subcutaneously.
Study: NCT06555757

Intervention type: OTHER
Intervention: Height, weight, and BMI
Description: Height, weight measurement and BMI calculation

Intervention type: OTHER
Intervention: Medical history
Description: Brief medical history including medications/allergies and heart failure related healthcare utilisation over previous 12 months

Intervention type: OTHER
Intervention: Physical examination
Description: Brief physical examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood samples
Description: Venous blood samples, to include WCC, HB, CRP and NTproBNP

Intervention type: OTHER
Intervention: Resting vital signs
Description: HR, BP, RR, oxygen saturations on air)

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiogram
Description: LVEF, IVC collapsibility, LV filling pressure, PA pressure

Intervention type: OTHER
Intervention: Sound recordings
Description: Sound recordings (voice/cough/chest) recorded with the in-built microphone in a smartphone

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound
Description: Lung ultrasound

Intervention type: OTHER
Intervention: KCCQ questionnaire
Description: Kansas City Cardiomyopathy Questionnaire

Intervention type: OTHER
Intervention: ASCEND-HF score
Description: An in-hospital congestion score which risk stratifies patients admitted with worsening heart failure, developed for the Acute study of clinical effectiveness of Nesiritide in decompensated heart failure trial

Intervention type: OTHER
Intervention: Composite Everest congestion score
Description: A shortened version of the original 18-point score from the EVEREST trial
Study: NCT05590741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Regulation Therapy via Telehealth
Description: The initial stage of treatment focuses on psychoeducation about anxiety/depression, the impact that these cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/anxiety/depression. The sessions focus on the development of skills that help understand and regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining session focuses on terminating therapy, relapse prevention, and future goals. An Internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, session summaries, worksheets).
Study: NCT06553066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep neuromascular blockage
Description: maintenance of a deep neuromuscular block with rocuronium, titrated to maintain a TOF count of 0, and a PTC between 1-2.~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale(Leiden scale : 1 indicates extremely poor conditions, 2 poor conditions, 3 acceptable conditions, 4, good conditions and 5 optimal conditions)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deep neuromascular blockage
Description: maintenance of a deep neuromuscular block with rocuronium, titrated to maintain a TOF count of 0, and a PTC between 1-2.~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale(Leiden scale : 1 indicates extremely poor conditions, 2 poor conditions, 3 acceptable conditions, 4, good conditions and 5 optimal conditions)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moderate neuromascular blockage
Description: maintenance of a moderate neuromuscular block with rocuronium, titrated to maintain a TOF count of 1-2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moderate neuromascular blockage
Description: maintenance of a moderate neuromuscular block with rocuronium, titrated to maintain a TOF count of 1-2
Study: NCT04027569

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Specific Functional Scale
Description: A validated patient reported outcome measure that asks patients to write down activities and score them 0 to 10.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMIS PF
Description: A computer adaptive, validated patient reported outcome measure that measures physical function on a 1 to 100.
Study: NCT06555757

Intervention type: DIAGNOSTIC_TEST
Intervention: Bio impedance and total body water measurement
Description: Bio impedance and total body water measurement using TANITA device
Study: NCT06012331

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: concentrated growth factors in open apex
Description: Dry canals with paper points. A 10 ml of venous blood will be collected and transferred to sterile tubes without anticoagulant solutions by a trained nurse. The tubes will be centrifuged machine using a one-step centrifugation protocol at variable rpm, after centrifugation, four layers will be obtained: the first layer at the top is serum, second layer is the fibrin buffy coat, the third layer is the liquid phase containing growth factors, The concentrated growth factor was separated from the red blood cells and serum using sterile scissors.~CGF will be packed into canal to the full working length using sterile pluggers.~The coronal level of the CGF gel is near the cervical area above cementoenamel junction and white MTA placed as capping material after CGF, then GIC and composite restoration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: concentrated growth factors in open apex
Description: Dry canals with paper points. A 10 ml of venous blood will be collected and transferred to sterile tubes without anticoagulant solutions by a trained nurse. The tubes will be centrifuged machine using a one-step centrifugation protocol at variable rpm, after centrifugation, four layers will be obtained: the first layer at the top is serum, second layer is the fibrin buffy coat, the third layer is the liquid phase containing growth factors, The concentrated growth factor was separated from the red blood cells and serum using sterile scissors.~CGF will be packed into canal to the full working length using sterile pluggers.~The coronal level of the CGF gel is near the cervical area above cementoenamel junction and white MTA placed as capping material after CGF, then GIC and composite restoration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Clot (BC)
Description: 1. Create bleeding into the canal by over-instrumenting (induce by rotating a pre-curved K-file at 2 mm past the apical foramen with the goal of having the entire canal filled with blood to CEJ level)~2. Stop bleeding at a level that allows for 3-4 mm of restorative material.~3. Then white MTA as a coronal plug material be followed by GIC, then composite restoration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Clot (BC)
Description: 1. Create bleeding into the canal by over-instrumenting (induce by rotating a pre-curved K-file at 2 mm past the apical foramen with the goal of having the entire canal filled with blood to CEJ level)~2. Stop bleeding at a level that allows for 3-4 mm of restorative material.~3. Then white MTA as a coronal plug material be followed by GIC, then composite restoration.
Study: NCT05567822

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol Hydrochloride
Description: In the esmolol group, patients will receive a bolus dose of esmolol followed by a continuous infusion of esmolol intraoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: In the placebo group, patients will receive a bolus dose of normal saline followed by a continuous infusion of normal saline intraoperatively
Study: NCT04603183

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 90 mg/m² infused over 1 hour on Days 1, 8, and 15 of the 28 day cycle, with at least a 6-day time span between separated doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Patients will receive 2.5 mg letrozole, orally administered and taken daily during each 28-day cycle combined with abemaciclib.
Study: NCT04834739

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SF-12
Description: The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality of life measure.
Study: NCT04603183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Patients will receive 500 mg fulvestrant, by intramuscular \[IM\] administration on Days 1 and 15 (±3 days) of the first treatment cycle and Day 1 of each cycle thereafter combined with abemaciclib.
Study: NCT06032182

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRESTR Intervention
Description: 15 1-hour sessions of CRT + SRT

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CRESTR Control
Description: 15 1-hour sessions of SRT alone
Study: NCT05700409

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive lifestyle consultations
Description: detailed above

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle consultations
Description: detailed above
Study: NCT05595109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silymarin
Description: Silymarin administration prevent the neuro-degeneration through inhibiting the activation of microglia, silymarin attenuates the activation of glial cell activation in cellular models possibly through inhibition of inducible nitric oxide synthase (iNOS) production, also reported to protect both microglia and astroglia from oxidative insults induced by peroxide in ex vivo system .~It also significantly reduces doxorubicin-pro-oxidative activity and decreases histological changes in liver and heart tissue . The hepato-protective and cardio-protective effects of silymarin may be attributed to its antioxidant capacity, its ability to prevent lipid peroxidation and its ability to increase glutathione concentration.~silymarin was reported to improve cognitive impairment in mice.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: which will receive four cycles of AC regimen (doxorubicin and cyclophosphamide; each cycle was given every 21 day) followed by 12 cycles of paclitaxel (each cycle was given in a weekly basis) plus placebo tablets once daily.
Study: NCT05412524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: reading
Description: Mothers and, if desired, mother's partner will read to preterm infant as frequently and as much as they are able to. Reading is the intervention. The variable of interest is parents' and infants' change in salivary oxytocin receptor gene methylation (OXTRm) over time.
Study: NCT05333224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Family-centered, goal-oriented early physiotherapy approaches will be applied.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Family-centered, goal-oriented early physiotherapy approaches will be applied.
Study: NCT05002686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200 mg Q3W on Day 1 by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Paclitaxel
Description: 200 mg/m\^2 Q3W on Day 1 by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m\^2 orally according to Body Surface Area (BSA) BID Q3W on Days 1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m\^2 Q3W on Day 1 by IV infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiotherapy for gastric lesions and high-risk areas of retroperitoneal lymph node before sugery, 45Gy\*25.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical gastric cancer surgery
Description: Radical gastric cancer surgery with D2 lymph node dissection
Study: NCT04998422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HG381
Description: HG381 is available as white to off-white cake or powder for solution for injection at a unit dose strength of 5 mg per vial. HG381 will be administered as IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HG381
Description: HG381 is available as white to off-white cake or powder for solution for injection at a unit dose strength of 5 mg per vial. HG381 will be administered as IV injection.
Study: NCT05282979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tixel 2
Description: Thermo-mechanical technology for fractional treatment of human skin. Dermal heating and coagulative effect that occur during the treatment session provide dermal remodeling and collagen restructuring that promote wrinkles appearance improvement.
Study: NCT05487365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comunicare Solutions Smartphone Application
Description: The Comunicare patient support solution is specifically designed for digital support of HF. It consists of an application for patients and a dashboard for the caregivers. The application is a class 1 certified medical device. It includes different modules for patient education, medication adherence, symptoms tracking, electronic patient-reported outcome (ePRO), appointments, and video consultation. Caregiver dashboard application: this web-based application enables caregivers to administrate the care flow and review all patient-reported data and the alarm generated by the system. Security and Privacy: the application complies with strict security and privacy-related regulations. All data storages are encrypted on the patients' smartphone and a server located in an ISO-certified data center located in Belgium, and all information exchanges are highly secured. A GDPR-compliant privacy notice defines how patient personal data is processed and how data protection principles are applied.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Completing a quality of life (QOL)-questionnaire
Description: Patients refusing to use Comunicare app will also be asked to complete a quality of life (QOL)-questionnaire at 0, 6 and 12 months which will be answered online.
Study: NCT05466175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olverembatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given Intravenous
Study: NCT05114759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2009
Description: In dose Escalation:~SHR-A2009 will be administered intravenously. Six dose levels are preset.~In dose Expansion:~2 to 3 dose cohorts will be selected for dose expansion stage.~In indication Expansion:~Indications will be selected to evaluate preliminary efficacy.
Study: NCT05563818

Intervention type: OTHER
Intervention: WinterLight Mobile Phone Speech Analysis
Description: N/A- observational study